ChatGPT

Perplexity

Gemini

Claude

Grok

GMED is an online scientific portal designed for Health Care Providers (HCPs) in the Middle East region.
GMED provides HCPs with high-quality scientific content created by renowned experts from the re

The Gilead Event App houses multiple Gilead Events within the app.  It is used to share information with event participants.  Key features include event agenda, speakers, exhibitor details, participan

HIV Answers
Gilead Sciences, Inc. 

Looking for HIV information and not sure where to start? HIV Answers can help. Download now to get:

•	Clear answers to questions about HIV
•	A step-by-step guide t

This is an educational platform is created by Gilead Sciences Middle East & KIT.
In this platform, you can find balanced & educational resources about therapeutic areas of interest for Gilead Sciences

We are trusted to always do the right thing and are responsible for our outcomes, delivering outstanding quality in all that we do with a high degree of integrity, pride and professionalism.

Integrity

We celebrate and respect each other's unique backgrounds, perspectives and experiences, creating an inclusive and respectful environment where all employees feel welcome and valued. Added as a core value in 2016.

Inclusion

We foster an employee culture that promotes collaboration, innovation, and a commitment to the progression and personal development of all colleagues, empowering employees to bring their whole selves to work.

Teamwork

We take responsibility for our commitments and outcomes, ensuring we deliver on our promises to patients, partners, and stakeholders with the highest standards of excellence.

Accountability

We value bold ideas and cultivate an environment in which everyone can grow and thrive, both professionally and personally, maintaining our commitment to science and patients.

Excellence

Gilead Sciences is a leading biopharmaceutical company that researches, develops, and commercializes innovative antiviral medicines to treat life-threatening infectious diseases including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. The company serves over 35 million patients globally across more than 100 countries.

Gilead Sciences agrees to pay $202M to settle claims of kickbacks for HIV drug

U.S. loses HIV patent suit against Gilead Sciences over PrEP

Amygdala Neurosciences Acquires GS-6637 from Gilead Sciences

Gilead Covid-19 Treatment Granted “Rare Disease” Status, Limiting Affordability

U.S. FDA approves Gilead cancer gene therapy; price set at $373,000

Daniel O'Day

Chairman of the Board and Chief Executive Officer

Andrew Dickinson

Chief Financial Officer

Johanna Mercier

Chief Commercial Officer

Dr. Dietmar Berger

Chief Medical Officer

Flavius Martin

Executive Vice President, Research

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s.

https://en.wikipedia.org/wiki/Gilead_Sciences

A complete single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults and pediatric patients. Biktarvy has become one of the leading HIV treatment options globally.

Biktarvy

The first and only twice-yearly HIV pre-exposure prophylaxis (PrEP) option approved by the FDA in June 2025. Clinical trials demonstrated 100% efficacy in preventing HIV infection in cisgender women, representing a revolutionary advancement in HIV prevention.

Yeztugo (Lenacapavir)

A nucleotide analog prodrug antiviral that serves as the standard of care for treating hospitalized COVID-19 patients and reducing disease progression in non-hospitalized high-risk patients. Approved in over 50 countries with approximately 14.5 million patients treated globally.

Veklury (Remdesivir)

A breakthrough direct-acting antiviral for hepatitis C virus treatment with cure rates exceeding 90%. Sovaldi revolutionized HCV treatment and became one of Gilead's most successful products following its 2013 FDA approval.

Sovaldi (Sofosbuvir)

A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate approved for both HIV treatment and prevention (PrEP). Truvada was the first FDA-approved medication for HIV prevention in 2012.

Truvada

A treatment for primary biliary cholangitis (PBC), a rare autoimmune liver disease. Approved by the FDA in August 2024 following Gilead's acquisition of CymaBay Therapeutics.

Livdelzi (Seladelpar)

A CAR T-cell therapy for certain types of large B-cell lymphoma, developed through Gilead's Kite Pharma subsidiary. Yescarta represents Gilead's leadership in cell therapy and oncology.

Yescarta (Axicabtagene Ciloleucel)

The FDA approved Yeztugo (lenacapavir) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents. This marks the first and only twice-yearly HIV PrEP option available in the United States, reviewed under priority review designation.

Gilead's Yeztugo Wins FDA Approval as First Twice-Yearly HIV Prevention

Kite, a Gilead subsidiary, announced the acquisition of Interius BioTherapeutics for $350 million in cash. The deal focuses on Interius's innovative in vivo CAR therapeutics platform, which enables CAR T-cell generation directly within patients through a single intravenous infusion.

Gilead Acquires Interius BioTherapeutics for $350 Million

Gilead announced full year 2024 revenue increased 6% to $28.8 billion compared to 2023, driven by higher sales in HIV, Oncology, and Liver Disease products. The company reported adjusted earnings per share of $7.24 and raised guidance for 2025.

Gilead Sciences Reports Strong Full Year 2024 Financial Results

The FDA approved Livdelzi (seladelpar), a treatment for primary biliary cholangitis (PBC), a rare autoimmune liver disease. The approval came just months after Gilead completed its $4.3 billion acquisition of CymaBay Therapeutics in February 2024.

FDA Approves Gilead's Livdelzi for Rare Liver Disease

Gilead Sciences completed the acquisition of CymaBay Therapeutics for $32.50 per share in cash, or a total equity value of $4.3 billion. The deal adds seladelpar, an investigational treatment for primary biliary cholangitis, to Gilead's existing liver disease portfolio.

Gilead Expands Liver Portfolio With $4.3B CymaBay Acquisition

Gilead announced that its Phase III PURPOSE 1 clinical trial demonstrated 100% efficacy of lenacapavir in preventing HIV infection in cisgender women. The twice-yearly injectable represents a potential breakthrough in HIV prevention, particularly in high-prevalence regions.

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trial

Gilead Sciences was once again included on the Dow Jones Sustainability World Index as one of the most sustainable pharmaceutical companies in 2024, marking the fourth consecutive year of recognition. The company was also ranked in the top five of America's Most Just Companies in biopharma for 2025.

Gilead Named to Dow Jones Sustainability Index for Fourth Consecutive Year

Gilead Sciences to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs ABI-1179 and ABI-5366 for Recurrent Genital Herpes

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Buy Signal Gilead Sciences Inc - 30 Mar 2026 @ 15:22 -&gt; USD135.88

Gilead Sciences, Inc.

Buy Signal Gilead Sciences Inc - 23 Mar 2026 @ 12:10 -&gt; USD137.30

getagraph

HerpesCureResearch

AnythingGoesNews

Quantisnow

edgar_news

healthrelatednews

GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)

Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences

Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences

Corporate Moral Responsibility, Distributive Justice, the Common Good, and Catholic Social Teaching: The Case of Gilead Sciences and Remdesivir

‘Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences’ by Roussel and Raoult (2020)

Helicase–primase inhibitors for the treatment of herpes simplex virus infections – patent evaluation of WO2023/225162 from Gilead Sciences Inc

WHO and Gilead Sciences extend collaborative agreement to enhance access to treatment for visceral leishmaniasis

Strategic Investment Decisions in the Post-Pandemic Pharmaceutical Market: A Case Study of Johnson & Johnson, Amgen, Gilead Sciences, and Regeneron Pharmaceuticals

Michael L. Riordan founded the company as Oligogen in Foster City, California, with $2 million in initial venture capital funding. The name referenced oligonucleotides, small DNA strands used to target genetic sequences.

Company Founded as Oligogen

After resolving trademark issues, the company was renamed Gilead Sciences, inspired by the Balm of Gilead. Donald Rumsfeld joined the board of directors.

Renamed to Gilead Sciences

Gilead debuted on the NASDAQ stock exchange, raising $86.25 million in proceeds from its IPO, providing crucial capital for drug development programs.

Initial Public Offering

Gilead launched Vistide (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS, marking the company's entry into the antiviral therapeutics market.

First Product Launch: Vistide

Gilead achieved profitability for the first time, 14 years after the company's founding, following years of investment in research and development.

First Full Year of Profitability

Gilead acquired Myogen, Inc. for $2.5 billion (its largest acquisition at the time) and Corus Pharma for $365 million, signaling the company's entry into the respiratory arena.

Major Acquisitions: Myogen and Corus Pharma

Gilead acquired Pharmasset, Inc. for $10.4 billion in its most important acquisition, cementing the company's leadership position in hepatitis C virus treatment and paving the way for Sovaldi's development.

Pharmasset Acquisition

The FDA approved Gilead's Truvada for prevention of HIV infection (PrEP) as a preventive measure for people at high risk of getting HIV through sexual activity, revolutionizing HIV prevention.

Truvada Approved for HIV Prevention

The FDA approved Sovaldi as a breakthrough treatment for hepatitis C virus, transforming HCV treatment with cure rates exceeding 90% and generating blockbuster revenues for Gilead.

Sovaldi FDA Approval

Gilead acquired Kite Pharma for $11.9 billion at $180 cash per share, marking the company's strategic entry into the cell therapy market and expanding beyond traditional antivirals.

Kite Pharma Acquisition

Gilead completed the acquisition of Forty Seven, Inc. for approximately $4.9 billion ($95.50 per share), strengthening its oncology pipeline with novel cancer immunotherapy approaches.

Forty Seven Inc. Acquisition

Gilead's remdesivir (Veklury) received emergency use authorization for COVID-19 treatment, becoming the antiviral standard of care for hospitalized patients and eventually treating 14.5 million patients worldwide.

Remdesivir Emergency Authorization

Gilead acquired CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio with seladelpar for primary biliary cholangitis treatment.

CymaBay Therapeutics Acquisition

The FDA approved Livdelzi (seladelpar) for the rare liver disease primary biliary cholangitis, just months after acquiring CymaBay Therapeutics.

Livdelzi FDA Approval

The FDA approved Yeztugo (lenacapavir) as the first and only twice-yearly HIV prevention option in the United States under priority review, representing a major breakthrough in HIV prevention.

Yeztugo FDA Approval

Never miss another birthday or anniversary. Kindful helps you be more thoughtful with smart reminders, personalized gift suggestions, and organized wishlists for everyone you care about.

  WHY THOUSA

Gilead Sciences vs Kindful

Gilead Sciences

About

Kindful

About

AI Visibility Head-to-Head

Also Compare

Track AI Visibility in Real Time